CVM - MCAP CO - CEL-SCI Corporation

The specifics of oncology treatment are independent of market cycles, as the demand for therapy remains stable and business development is driven by scientific test results. The absence of profitable products creates long-term inertia, leaving the company reliant on external financing, with the indicator standing at 0.03. Current price action on GURU.Markets reflects the position of CEL-SCI Corporation (CVM), the developer of the immune drug Multikine for patients with head and neck cancer.

The uniqueness of Multikine technology in cancer immunotherapy drives the investment appeal of CEL-SCI Corporation (CVM). The company's capitalization dynamics reflect the market valuation of this technological advantage. This figure is calculated as the product of the current share price and the total number of outstanding securities. This metric measures the aggregate business value and its ability to attract institutional capital. Variance analysis helps investors assess asset liquidity and volatility risks.